Bone marrow ‐ mesenchymal stem cells impact on the U937 cells in the presence of staphylococcal enterotoxin B (<scp>SEB</scp>)

Ejtehadifar, Mostafa; Halabian, Raheleh; Ghazavi, Ali; Khansarinejad, Behzad; Mosayebi, Ghasem; Fooladi, Abbas Ali Imani

doi:10.1111/1440-1681.12945

Cited by 1 publication

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This feature makes the SAg very attractive for immunotherapy. Superantigens have been heavily studied for cancer immunotherapy as it is effective in T-cell-dependent tumor killing [ 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. To minimize cytotoxicity by the massive immune cell activation in the body, SAgs have been fused to anticancer antibody fragments to specifically target the induced T-cell activity towards cancer cells [ 31 , 32 , 33 , 34 ].…”

Section: Introductionmentioning

confidence: 99%

Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy

Bashraheel

Goda

2023

IJMS

View full text Add to dashboard Cite

Bacterial superantigens (SAgs) are effective T-cell stimulatory molecules that lead to massive cytokine production. Superantigens crosslink between MHC class II molecules on the Antigen Presenting Cells (APC) and TCR on T-cells. This enables them to activate up to 20% of resting T cells, whilst conventional antigen presentation results in the activation of 0.001–0.0001% of the T cell population. These biological properties of superantigens make them attractive for use in immunotherapy. Previous studies have established the effectiveness of superantigens as therapeutic agents. This, however, was achieved with severe side effects due to the high lethality of the native toxins. Our study aims to produce superantigen-based peptides with minimum or no lethality for safer cancer treatment. In previous work, we designed and synthesized twenty overlapping SPEA-based peptides and successfully mapped regions in SPEA superantigen, causing a vasodilatory response. We screened 20 overlapping SPEA-based peptides designed and synthesized to cover the whole SPEA molecule for T-cell activation and tumor-killing ability. In addition, we designed and synthesized tumor-targeted superantigen-based peptides by fusion of TGFαL3 either from the N′ or C′ terminal of selected SPEA-based peptides with an eight-amino acid flexible linker in between. Our study identified parts of SPEA capable of stimulating human T-cells and producing different cytokines. We also demonstrated that the SPEA-based peptide conjugate binds specifically to cancer cells and can kill this cancer. Peptides induce T-cell activation, and tumor killing might pave the way for safer tumor-targeted superantigens (TTS). We proposed the combination of our new superantigen-based peptide conjugates with other immunotherapy techniques for effective and safer cancer treatment.

show abstract